Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Atherosclerosis. 2015 Oct 30;244:22–28. doi: 10.1016/j.atherosclerosis.2015.10.103

Table 2.

Lipidomic analysis

Lipid Species HIV Negative WT HIV ΔNef-HIV
PS 36:1 1418.5 ± 935.8 259.5 ± 259.9** 7733.5 ± 9425.3#
PS 38:3 299.8 ± 158.4 53.8 ± 91.9* 1559.4 ± 1791.7#
PS 40:5 123.0 ± 65.5 13.6 ± 33.4** 590.9 ± 659.4#
PS (total) 2161.5 ± 1317.7 334.2 ± 121.4* 10,772.2 ± 12,619.5#
dhCer 20:0 20.8 ± 5.6 23.4 ± 9.1 115.7 ± 125.8*
Cer 18:0 80.4 ± 16 102.9 ± 26.6 140.7 ± 76.9*
SM 32:0 423.0 ± 84.8 512.0 ± 136.4 666.2 ± 176.0*
SM 34:0 4,369 ± 686.2 5,402.1 ± 1,442.6 6,326 ± 803.1**
PE(O-36:6) 34.3 ± 10.4 71.7 ± 44.9 95.4 ± 32.5**
dhCer (total) 519.0 ± 77.7 571.9 ± 254.3 1439.2 ± 1033.8*
PI 34:0 153.5 ± 58.0 362.2 ± 298.8* 342.8 ± 287.7
dhCer 16:0 46.3 ± 6.7 71.5 ± 15.7* 120.7 ± 70.5**
dhCer 18:0 46.1 ± 11.4 79.6 ± 22.0* 194.1 ± 184.3*
DHC 20:0 111.3 ± 38.4 85.0 ± 38.6 256.2 ± 249.5#
PE(22:6/0:0) 1378.0 ± 402.6 1723.5 ± 836.7 1042.8 ± 168.4#
PS 40:6 128.4 ± 53.9 36.6 ± 49.7 572.1 ± 619.6#

Abbreviations: dhCer, dihydroceramide; Cer, ceramide; DHC, dihexosylceramide; PE, phosphatidylethanolamine; PE(O), alkylphosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin;

*

p < 0.05 vs HIV Negative;

**

p < 0.01 vs HIV Negative;

#

p < 0.05 vs WT HIV (ANOVA)